Noah & Zoey Partner with Novo Nordisk to Tackle Hong Kong’s Hidden Obesity Challenge

Noah & Zoey, the digital health brands under Ordinary Folk, have announced a partnership with global healthcare leader Novo Nordisk to transform how obesity care is delivered in Hong Kong. This marks the first time Wegovy has been made available through a fully digital care model in Hong Kong, giving patients seamless access to the world’s leading GLP-1 therapy for chronic weight management through Noah & Zoey’s telemedicine platforms.

A health crisis hidden in plain sight

While obesity rates in Hong Kong continue to climb, the problem often goes unseen. According to the Centre for Health Protection’s Population Health Survey 2020–22, 32.6% of adults are classified as obese, with another 22% overweight.¹ Yet a 2025 survey by The Standard found that over 70% of Hongkongers still don’t recognise obesity as a chronic disease.²

Research shows that Asians tend to carry 20-25 per cent more visceral fat than Caucasians at the same BMI³, which increases the risk of type 2 diabetes, hypertension, and cardiovascular disease even in people who appear slim. This gap between perception and biology has kept many people from seeking proper, evidence-based care.
‍
“‘Hidden obesity’ is a uniquely Asian challenge, and it keeps people from seeking proper care,” said Sean Low, Founder of Noah & Zoey. “By bringing Wegovy onto our platform, we’re bridging the gap between medical innovation and everyday access, so people can receive safe, credible care without friction or judgement.”

Changing how Hong Kong approaches obesity care
‍
Through Noah & Zoey, eligible patients can now consult licensed Hong Kong doctors, receive medically guided care, including prescriptions for Wegovy. From initial consultation to prescription fulfilment and ongoing follow-up, every step takes place digitally - removing traditional barriers such as geography, stigma, and clinic wait times.

“Partnering with Noah & Zoey allows us to reach more people living with obesity through trusted, patient-centred digital care,” said Anirvan Dutt-Chaudhuri, General Manager for Hong Kong SAR and Macau at Novo Nordisk. “Together, we’re making proven treatment more accessible and helping to reshape how obesity is understood and managed in Hong Kong.”

The future: proactive, data-driven care

Beyond expanding access to Wegovy, Noah & Zoey are developing AI-powered tools to help patients and doctors take a more proactive, personalised approach to obesity management. These technologies will combine treatment data, tracking, and lifestyle insights to help people stay engaged, measure progress, and achieve sustainable results.

“Our mission is to improve long-term health outcomes in Asia,” added Low. “These technologies enable more informed, continuous care helping patients not only begin treatment but stay supported throughout their health journey.”